You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
|
|---|---|
| Published in |
Journal of Clinical Oncology, September 2012
|
| DOI | 10.1200/jco.2011.41.3799 |
| Pubmed ID | |
| Authors |
Alexander M.M. Eggermont, Stefan Suciu, Alessandro Testori, Mario Santinami, Wim H.J. Kruit, Jeremy Marsden, Cornelis J.A. Punt, François Salès, Reinhard Dummer, Caroline Robert, Dirk Schadendorf, Poulam M. Patel, Gaetan de Schaetzen, Alan Spatz, Ulrich Keilholz |
| Abstract |
Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results of this pivotal trial. |
Mendeley readers
The data shown below were compiled from readership statistics for 136 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 2 | 1% |
| Brazil | 2 | 1% |
| United Kingdom | 1 | <1% |
| Belgium | 1 | <1% |
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 128 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 35 | 26% |
| Other | 20 | 15% |
| Student > Bachelor | 13 | 10% |
| Student > Master | 11 | 8% |
| Student > Ph. D. Student | 10 | 7% |
| Other | 30 | 22% |
| Unknown | 17 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 71 | 52% |
| Biochemistry, Genetics and Molecular Biology | 15 | 11% |
| Immunology and Microbiology | 8 | 6% |
| Agricultural and Biological Sciences | 6 | 4% |
| Business, Management and Accounting | 2 | 1% |
| Other | 11 | 8% |
| Unknown | 23 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2023.
All research outputs
#4,835,823
of 25,373,627 outputs
Outputs from Journal of Clinical Oncology
#8,926
of 22,043 outputs
Outputs of similar age
#34,642
of 190,199 outputs
Outputs of similar age from Journal of Clinical Oncology
#62
of 208 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,043 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 190,199 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 208 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.